AVITA Medical, Inc. (RCEL) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed outlook. Financial performance showed a revenue decline and reduced margins, but cost management improved the operating loss and net loss. The Q&A reveals management's focus on U.S. growth, reimbursement normalization, and resource allocation challenges. However, lowered 2025 guidance, under-penetration, and lack of clear European strategy weigh on sentiment. Despite some positives like reduced expenses and cash position improvement, the overall sentiment remains neutral due to mixed guidance and uncertainties in execution.
Key Financial Performance
Revenue $17.1 million for Q3 2025, a 13% year-over-year decline from $19.5 million in Q3 2024. The decline was primarily due to temporary reimbursement headwinds and the timing of hospital VAC reviews.
Gross Profit Margin 81.3% for Q3 2025, down from 83.7% in Q3 2024. The decline was driven by product mix, including the increasing contribution of Cohealyx and PermeaDerm to overall revenue, and other inventory-related adjustments.
Operating Expenses $23 million for Q3 2025, down 24% year-over-year from $30.2 million in Q3 2024. The reduction was due to cost reduction initiatives, including lower salaries, benefits, stock-based compensation, and reduced headcount.
Operating Loss $9.2 million for Q3 2025, a 34% improvement year-over-year from $13.8 million in Q3 2024. This improvement reflects reduced operating expenses.
Net Loss $13.2 million for Q3 2025, a 19% improvement year-over-year from $16.2 million in Q3 2024. The improvement was due to cost management and reduced operating expenses.
Cash Position $23.3 million as of September 30, 2025, up from $15.7 million at the beginning of the quarter. This increase was due to a $13.8 million private placement and improved cash management, including a 40% reduction in operating cash use quarter-over-quarter.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
RECELL GO CE Mark approval: Received CE Mark approval in Europe in September, with the first patient treated in Germany.
Cohealyx: VAC submissions are underway in roughly 1/3 of target accounts, with positive clinical feedback and expected full enrollment by year-end.
PermeaDerm: Continues to perform well as a versatile biosynthetic dressing, with early results from PermeaDerm-I study being encouraging.
Market focus: Refined focus on 200 burn centers and trauma hospitals in the U.S., representing $1.3 billion of the $3.5 billion total addressable market.
Global expansion: Broadened access to RECELL technology with the first European treatment using RECELL GO.
Reimbursement clarity: All 7 MACs have published or confirmed reimbursement rates for RECELL, restoring clinician confidence and driving renewed demand.
Cost management: Reduced operating expenses by 24% year-over-year, achieving a leaner cost structure and improved cash management.
Commercial organization restructuring: Aligned structure, territories, and accountability around high-value accounts to improve focus and execution.
Forecasting improvements: Enhanced forecasting model to provide a more accurate view of future revenue.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Decline: The company reported $17 million in revenue for the quarter, below expectations and reflecting a 13% year-over-year decline. This was primarily due to reimbursement disruptions and delays in hospital Value Analysis Committee (VAC) reviews.
Reimbursement Disruption: New Category I CPT codes for RECELL procedures caused reimbursement uncertainty as regional Medicare Administrative Contractors (MACs) took time to set rates. This led to providers delaying or reducing usage of RECELL, impacting revenue.
Delayed Hospital VAC Reviews: The pace of hospital VAC reviews has been slower than anticipated, delaying the adoption and ordering of products like Cohealyx and PermeaDerm.
Commercial Organization Transition: The company is undergoing a transition in its commercial organization, which has temporarily limited near-term results and created challenges in execution and forecasting.
Cost Management Challenges: While operating expenses have been reduced, the company still faces challenges in achieving cash flow breakeven and maintaining financial sustainability.
Debt Covenant Risks: The company had to secure a waiver for its Q3 revenue covenant under the OrbiMed credit agreement and lowered its Q4 revenue covenant, indicating financial strain and potential risks in meeting future debt obligations.
Market Penetration Challenges: Despite a $3.5 billion total addressable market, the company is currently serving only 5% of its targeted $1.3 billion segment, highlighting significant under-penetration.
Product Utilization Consistency: The company faces challenges in driving consistent utilization of its products, which is critical for predictable revenue and growth.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: Full year revenue is now expected to be in the range of $70 million to $74 million, revised down from the prior guidance of $76 million to $81 million. This adjustment reflects slower-than-anticipated reimbursement normalization and measured expectations for RECELL demand and utilization through year-end.
Market Recovery and Utilization: Reimbursement clarity for RECELL has been achieved, with all 7 MACs publishing or confirming provider reimbursement rates. This is expected to progressively normalize utilization and rebuild order momentum in the coming quarters.
Growth Potential and Market Focus: The company is focusing on 200 core burn centers and trauma hospitals, representing $1.3 billion in targeted opportunity within a broader $3.5 billion U.S. market. Currently serving about 5% of this segment, providing significant runway for penetration and growth.
Product Development and Clinical Studies: Cohealyx VAC submissions are underway in roughly 1/3 of target accounts, with ordering expected to build steadily over the coming quarters. Full enrollment for the Cohealyx I study is expected by year-end, with results anticipated early next year. PermeaDerm-I study data is also expected next year.
Financial Discipline and Capital Strategy: The company is maintaining balance sheet flexibility and conserving cash while supporting operations. An update on financial outlook, including 2026 revenue and guidance, will be provided in early Q1 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What initiatives are being taken to better forecast the business as 2026 approaches?
A:The company is focusing on understanding customer utilization and purchasing patterns at the rep and customer levels. They have implemented strong modeling in their sales support structure and believe that with the processes, people, and leadership in place, forecasting will improve significantly.
Q:How is the company balancing resources for launching in Europe versus stabilizing the U.S. business?
A:The primary focus is on the U.S. market. Limited resources will be allocated to Europe, with efforts concentrated on selecting distributors, understanding customers, and gaining traction in select markets. The company is committed to Europe but remains focused on U.S. growth.
Q:How is the company addressing reimbursement normalization and confidence among accounts?
A:The company is educating accounts about new CPT codes and ensuring they see reimbursement in action. Efforts are being made to minimize the lag between MAC approvals and account confidence. Claims dating back to January will be adjudicated, which is expected to boost physician confidence.
Q:What is the update on VAC approvals for Cohealyx and account readiness for 2026?
A:About one-third of accounts are in the VAC process, with two-thirds expected to come out in Q4. The company is working to minimize delays between approval, ordering, and utilization. Teams are preparing to ensure a smooth transition post-approval.
Q:Are there accounts where RECELL, Cohealyx, and PermeaDerm are all available, and are there any observed synergies?
A:Some accounts have all three products approved and are using them on wounds. However, it is still early to assess momentum or synergies. The company plans to provide more information in the future.
Q:What is the spending outlook given the current balance sheet and cash profile?
A:The company believes its G&A and sales team structures are appropriately sized and disciplined. Cash use has declined due to restructuring, and the focus is now on revenue growth to achieve profitability and cash flow breakeven.
Q:Is there a plan to change the sales team incentive structure?
A:The company is reviewing 2026 compensation plans to ensure alignment with growth objectives. The plans will be simple, fair, and growth-oriented, but specifics are not yet finalized.
Q:Does current guidance factor in catch-up from reimbursement payment backlogs?
A:The guidance does not assume an immediate recovery from reimbursement backlogs. The company is rebuilding provider confidence, and a complete update on 2026 revenue guidance will be provided in early 2026.
Q:Is it too early to discuss breakeven targets?
A:Yes, it is too early. The company plans to provide more details on breakeven targets and revenue guidance in early 2026.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on breakeven targets and the momentum of accounts using all three products (RECELL, Cohealyx, and PermeaDerm). They also did not provide a clear timeline for when reimbursement normalization would fully restore account confidence or when European market efforts would yield significant results.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Chairman Interim
Independent Non
Interim CEO
MACs
Non Chairman
OrbiMed
RECELL PermeaDerm
RECELL procedure
VAC review
accountability
action
adjustment
amendment
balance sheet
capital
clarity
clinician hospital
confidence
cost
customer behavior
demand
focus
improvement
mission
payment
priority
progress
provider reimbursement
rate
reduction
slide
structure
team
timing
transition
use RECELL
utilization
wound healing
RCEL Transcript
AVITA Medical, Inc. (RCEL) Q1 2026 Earnings Call Transcript
Positive5-14
The company reported a 25% YoY revenue increase and improved gross margin, indicating strong financial performance. Despite a net loss, the reduction from the previous year and controlled operating expenses are positive signs. The cash position is also stable. Although no strategic initiatives or risks were discussed, the financial results and improved margins suggest a positive outlook. Given the absence of market cap data, a cautious 'Positive' sentiment is assigned.
AVITA Medical, Inc. (RCEL) Q4 2025 Earnings Call Transcript
Unknown2-12
The earnings call reveals mixed signals. While the company shows revenue growth and improved cash usage, it has revised revenue guidance downward and faces gross margin pressure. The Q&A indicates some uncertainty in reimbursement dynamics and product adoption, but no major red flags. The strategic focus on burn centers and new product lines offers growth potential. The overall sentiment is neutral, balancing positive financial discipline against cautious guidance and market challenges.
AVITA Medical, Inc. (RCEL) Q3 2025 Earnings Call Transcript
Unknown11-6
The earnings call presents a mixed outlook. Financial performance showed a revenue decline and reduced margins, but cost management improved the operating loss and net loss. The Q&A reveals management's focus on U.S. growth, reimbursement normalization, and resource allocation challenges. However, lowered 2025 guidance, under-penetration, and lack of clear European strategy weigh on sentiment. Despite some positives like reduced expenses and cash position improvement, the overall sentiment remains neutral due to mixed guidance and uncertainties in execution.
AVITA Medical, Inc. (RCEL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Neutral9-8
RCEL Slides
RCEL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
